783 results on '"Hoermann, Gregor"'
Search Results
2. Parallel genomic analysis from paired bone marrow and peripheral blood samples of 200 cytopenic patients
3. Genomic landscape of CCUS compared to MDS and its implications on risk prediction
4. CAR virus receptor mediates erythroid differentiation and migration and is downregulated in MDS
5. Risk assessment according to IPSS-M is superior to AML ELN risk classification in MDS/AML overlap patients defined by ICC
6. A lineage-specific STAT5BN642H mouse model to study NK-cell leukemia
7. STAT3/LKB1 controls metastatic prostate cancer by regulating mTORC1/CREB pathway
8. Pulmonary recovery from COVID-19 in patients with metabolic diseases: a longitudinal prospective cohort study
9. Hyperactive STAT5 hijacks T cell receptor signaling and drives immature T cell acute lymphoblastic leukemia
10. AML classification in the year 2023: How to avoid a Babylonian confusion of languages
11. Comparing malignant monocytosis across the updated WHO and ICC classifications of 2022
12. Tumor necrosis factor α promotes clonal dominance of KIT D816V+ cells in mastocytosis: role of survivin and impact on prognosis
13. Precision Medicine in Therapy of Non-solid Cancer
14. Harmonization of Diagnostic Criteria in Mastocytosis for Use in Clinical Practice: WHO vs ICC vs AIM/ECNM
15. Engraftment in NSGSCF mice correlates with the WHO category and prognosis in systemic mastocytosis
16. MDS subclassification—do we still have to count blasts?
17. Risk prediction in MDS: independent validation of the IPSS-M—ready for routine?
18. Germ line variant GFI1-36N affects DNA repair and sensitizes AML cells to DNA damage and repair therapy
19. The Normal Range of Baseline Tryptase Should Be 1 to 15 ng/mL and Covers Healthy Individuals With HαT
20. SF3B1 mutations in AML are strongly associated with MECOM rearrangements and may be indicative of an MDS pre-phase
21. SF3B1 mutated MDS: Blast count, genetic co-abnormalities and their impact on classification and prognosis
22. European Competence Network on Mastocytosis (ECNM): 20-Year Jubilee, Updates, and Future Perspectives
23. SBNO2 is a critical mediator of STAT3-driven hematological malignancies
24. Mutations in spliceosome genes in myelodysplastic neoplasms and their association to ring sideroblasts
25. Clonal hematopoiesis of indeterminate potential: clinical relevance of an incidental finding in liquid profiling
26. Standards of Pathology in the Diagnosis of Systemic Mastocytosis: Recommendations of the EU-US Cooperative Group
27. Proposed European Competence Network on Mastocytosis—American Initiative in Mast Cell Diseases (ECNM-AIM) Response Criteria in Advanced Systemic Mastocytosis
28. Global Classification of Mast Cell Activation Disorders: An ICD-10-CM–Adjusted Proposal of the ECNM-AIM Consortium
29. Incorporating Tryptase Genotyping Into the Workup and Diagnosis of Mast Cell Diseases and Reactions
30. Personalized Management Strategies in Mast Cell Disorders: ECNM-AIM User’s Guide for Daily Clinical Practice
31. Standards of Genetic Testing in the Diagnosis and Prognostication of Systemic Mastocytosis in 2022: Recommendations of the EU-US Cooperative Group
32. Expert-level detection of M-proteins in serum protein electrophoresis using machine learning.
33. Can molecular patterns help to classify overlapping entities in myeloid neoplasms?
34. BRD4 degraders may effectively counteract therapeutic resistance of leukemic stem cells in AML and ALL.
35. Prevalence and Therapeutic Implications of Clonal Hematopoiesis of Indeterminate Potential in Young Patients With Stroke
36. Core‐binding factor acute myeloid leukemia with t(8;21): Risk factors and a novel scoring system (I‐CBFit)
37. Secondary basophilic leukemia in Ph-negative myeloid neoplasms: A distinct subset with poor prognosis
38. Classical meets malignant hematology: a case of acquired εγδβ-thalassemia in clonal hematopoiesis
39. A genome-wide association study identifies key modulators of complement factor H binding to malondialdehyde-epitopes
40. Precision Medicine in Therapy of Non-solid Cancer
41. Secondary cytogenetic abnormalities in core-binding factor AML harboring inv(16) vs t(8;21)
42. LMO3 reprograms visceral adipocyte metabolism during obesity
43. Hereditary α tryptasemia is a valid genetic biomarker for severe mediator-related symptoms in mastocytosis
44. Delineation of target expression profiles in CD34+/CD38− and CD34+/CD38+ stem and progenitor cells in AML and CML
45. Microarray-Based Detection of Allergen-Reactive IgE in Patients with Mastocytosis
46. TNF alpha promotes clonal dominance of KIT D816V+ cells in mastocytosis: role of survivin and impact on prognosis
47. Cardio-pathogenic variants in unexplained intrauterine fetal death: a retrospective pilot study
48. Cytomegalovirus in urinary sediment in patients with acute kidney injury
49. Consensus criteria for diagnosis, staging, and treatment response assessment of T-cell prolymphocytic leukemia
50. A lineage-specificSTAT5BN642Hmouse model to study NK-cell leukemia
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.